Sep 2026· Journal of Parkinson's Disease· 0 citations· 35 references
Medicine
TL;DR
Recommendations are made regarding necessary literature reviews, including qualitative data and related conceptual models, disease models including pathophysiology and neuropsychological profile, and clinical outcome assessment (COA) reviews, including content validity, psychometrics, and fitness-for-purpose.
Abstract
Cognitive dysfunction is a prevalent and impactful feature of Parkinson's disease (PD), with substantial heterogeneity in onset, severity, and progression, and a high lifetime risk of dementia. Despite its clinical importance, effective treatments and fit-for-purpose outcome measures remain limited. This article reports outcomes from a multi-stakeholder roundtable convened by The Michael J. Fox Foundation for Parkinson's Research, outlining priorities to advance patient-focused endpoints and improve clinical trial design to accelerate therapeutic development for cognitive dysfunction. In the context of the current understanding of cognitive impairment across the PD/dementia with Lewy bodies (DLB) spectrum and existing neuropsychological assessment approaches, recommendations are made regarding necessary literature reviews, including qualitative data and related conceptual models, disease models including pathophysiology and neuropsychological profile, and clinical outcome assessment (COA) reviews, including content validity, psychometrics, and fitness-for-purpose. Additionally, novel conceptual models of cognitive impairment across the normal, mild cognitive impairment (MCI) and dementia spectrum are needed and may require further qualitative evidence.
Purpose To provide an updated, clinically oriented overview of therapeutic strategies for Parkinson’s disease-related psychosis (PDP), integrating current evidence on risk factors and available pharmacological and non-pharmacological treatments. Patients and Methods This is a narrative, non-systematic review summarizin...
N. Rocha, Karina Lucia Moreira Sassi, Erin Furr Stimming et al.· Clinical Pharmacology : Adva...· 0 citations
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide accounting for an estimated 60% to 80% of cases. Biomarkers play an integral role in AD randomized clinical trials (RCTs), providing objective measures of disease pathology, progression, and therapeutic effi...
Xiao-Lan Zhang, Michael F. Murphy, Henry J. Riordan et al.· Bioanalysis· 0 citations
Background Cognitive impairment and neuropsychiatric manifestations are common disabling non-motor symptoms that can negatively impact quality of life in Parkinson's disease. This review aimed to critically appraise and synthesize evidence on the prevalence, predictors, and emerging biomarkers of cognitive impairment a...
M. Njohjam, F. Niakam, M. Ngoule· Journal of Parkinson's Disea...· 0 citations
BACKGROUND
In patients with fluctuating Parkinson's disease (PD), treatment decisions predominantly focus on motor complications, whereas neuropsychiatric symptoms are often regarded as static. Neuropsychiatric fluctuations (NPF), however, are frequent, can rival or exceed motor symptoms in their impact on quality of l...
M. Sousa, D. Amstutz, E. Natera-Villalba et al.· Movement Disorders Clinical...· 0 citations
Background: As people age, they grow more aware of brain health, and interest in keeping the mind sharp has grown alongside anti-aging culture. Neurologic disease is a leading global burden: stroke is the fifth leading cause of death, migraine is the second most burdensome neurological disorder, and more than 57 millio...
Joey R. Gee· Journal of the Osteopathic F...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.